Fig. 5

Validation performance in validation cohort 1 and validation cohort 2. a ROC curve analysis for the predictive power of validated lipid signatures in new plasma samples. b Performance of the model in new plasma cohort of ten COVID-19 patients. Samples classified into wrong group were labeled. c ROC curve analysis for the predictive power of validated lipid signatures in urine samples. d Performance of the model in urine cohort of ten COVID-19 patients. Samples classified into wrong group were labeled